HRP20171499T1 - Protutijela za humani gdf8 - Google Patents
Protutijela za humani gdf8 Download PDFInfo
- Publication number
- HRP20171499T1 HRP20171499T1 HRP20171499TT HRP20171499T HRP20171499T1 HR P20171499 T1 HRP20171499 T1 HR P20171499T1 HR P20171499T T HRP20171499T T HR P20171499TT HR P20171499 T HRP20171499 T HR P20171499T HR P20171499 T1 HRP20171499 T1 HR P20171499T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- binding fragment
- antibody
- seq
- amino acid
- Prior art date
Links
- 101100228739 Danio rerio mstnb gene Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 3
- 206010028289 Muscle atrophy Diseases 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000054677 human MSTN Human genes 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- 208000001076 sarcopenia Diseases 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010020100 Hip fracture Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000014101 glucose homeostasis Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Claims (10)
1. Izolirano humano protutijelo ili njegov fragment koji se veže na antigen, naznačen time, da se specifično veže na ili blokira biološku aktivnost divljeg tipa zrelog humanog GDF8 koji sadržava SEQ ID NO: 340, ali se ne veže na ili blokira biološku aktivnost himernog GDFB/TGF01 konstrukta koji sadržava aminokiseline 4872 zrelog humanog GDF8 zamijenjene odgovarajućom aminokiselinskom sekvencom TGFpi, pri čemu himerni GDF8/TGF01 konstrukt sadržava aminokiselinsku sekvencu SEQ ID NO: 352, i pri čemu protutijelo ili fragment koji veže antigen sadržava:
(a) HCDR1 / HCDR2 / HCDR3 aminokiselinske sekvence koje se sastoje od SEQ ID NO: 362/364/366, i
2. sekvence aminokiselina LCDR1 / LCDR2 / LCDR3 koje se sastoje od SEQ ID NO: 370/372/374.
2. Izolirano protutijelo ili fragment koji se veže na antigen u skladu s patentnim zahtjevom 1, naznačen time, da protutijelo ili fragment koji veže antigen sadržava: (a) CDR-ove teškog lanca (HCDR1, HCDR2 i HCDR3) iz varijabilne regije teškog lanca koja sadržava aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID NO: 360 i (b) CDR-ove lakog lanca (LCDR1, LCDR2 i LCDR3) iz varijabilne regije lakog lanca koja sadržava sekvencu aminokiselina koja se sastoji od SEQ ID NO: 368.
3. Izolirano protutijelo ili fragment koji se veže na antigen u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da protutijelo ili fragment koji se veže na antigen ne vežu na
(a) linearni epitop unutar divljeg tipa zrelog GDF8 (SEQ ID NO: 340); i / ili
(b) izolirane GDF8 peptide koji sadržavaju aminokiselinske sekvence aminokiselina 114, 1-18, 17-42, 48-65, 48-69, 48-72, 52-65, 52-72, 56-65, 56-72, 65-72, 73-90, 75-105 i 91-105 od SEQ ID NO: 340.
4. Farmaceutski pripravak, naznačen time, da sadržava protutijelo ili fragment koji se veže na antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 3 i farmaceutski prihvatljivi nosač ili razrjeđivač.
5. Izolirano protutijelo ili fragment koji se veže na antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time, da se upotrebljava u medicini.
6. Izolirano protutijelo ili fragment koji se veže na antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time, da se upotrebljava u liječenju pacijenta koji pati od, dijagnosticirana mu je ili je izložen riziku od bolesti ili poremećaja odabranih iz skupine koja se sastoji od sarkopenije, kaheksije i atrofije mišića zbog neaktivnosti ili imobilizacije.
7. Upotreba izoliranog protutijela ili fragmenta koji se veže na antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time, da se koristi u proizvodnji lijeka za uporabu u liječenju pacijenta koji pati od, dijagnosticirana mu je ili je izložen riziku od bolesti ili poremećaja odabranog iz skupine koja se sastoji od sarkopenije, kaheksije, gubitka mišića, atrofije mišića, raka, artritisa, multiple skleroze, amiotrofne lateralne skleroze, Parkinsonove bolesti, osteoporoze, osteoartritisa, osteopenije, frakture kostiju, uključujući frakture kuka, metaboličkih sindroma, homeostaze glukoze i osjetljivosti na inzulin.
8. Uporaba u skladu s patentnim zahtjevom 7, naznačena time, da je kaheksija idiopatska ili sekundarna u odnosu na druge uvjete.
9. Uporaba u skladu s patentnim zahtjevom 7, naznačena time, da je gubitak mišića ili atrofija uzrokovana ili povezana s neupotrebom mišića, imobilizacijom, ležajem, ozljedom, medicinskim tretmanom ili kirurškim zahvatom.
10. Upotreba u skladu s patentnim zahtjevom 7, naznačena time, da je metabolički sindrom odabran iz skupine koju čine dijabetes, pretilost, prehrambeni poremećaji, atrofija organa, kronična opstruktivna plućna bolest i anoreksija.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34855910P | 2010-05-26 | 2010-05-26 | |
| US37288210P | 2010-08-12 | 2010-08-12 | |
| PCT/US2011/037837 WO2011150008A1 (en) | 2010-05-26 | 2011-05-25 | Antibodies to human gdf8 |
| EP11726005.9A EP2576618B1 (en) | 2010-05-26 | 2011-05-25 | Antibodies to human gdf8 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171499T1 true HRP20171499T1 (hr) | 2017-11-17 |
Family
ID=44477626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171499TT HRP20171499T1 (hr) | 2010-05-26 | 2017-10-05 | Protutijela za humani gdf8 |
Country Status (40)
| Country | Link |
|---|---|
| US (5) | US8840894B2 (hr) |
| EP (1) | EP2576618B1 (hr) |
| JP (1) | JP5896993B2 (hr) |
| KR (1) | KR101859911B1 (hr) |
| CN (1) | CN102933602B (hr) |
| AR (1) | AR081221A1 (hr) |
| AU (1) | AU2011258342B2 (hr) |
| BR (1) | BR112012029986B1 (hr) |
| CA (1) | CA2800581C (hr) |
| CL (1) | CL2012003283A1 (hr) |
| CO (1) | CO6620013A2 (hr) |
| CR (1) | CR20120577A (hr) |
| CY (1) | CY1119445T1 (hr) |
| DK (1) | DK2576618T3 (hr) |
| DO (1) | DOP2012000295A (hr) |
| EC (1) | ECSP12012309A (hr) |
| ES (1) | ES2647389T3 (hr) |
| GT (1) | GT201200318A (hr) |
| HR (1) | HRP20171499T1 (hr) |
| HU (1) | HUE037140T2 (hr) |
| IL (1) | IL223003A (hr) |
| JO (1) | JO3340B1 (hr) |
| LT (1) | LT2576618T (hr) |
| MX (2) | MX2012013369A (hr) |
| MY (1) | MY157109A (hr) |
| NI (1) | NI201200171A (hr) |
| NO (1) | NO2576618T3 (hr) |
| NZ (1) | NZ603529A (hr) |
| PE (1) | PE20130226A1 (hr) |
| PL (1) | PL2576618T3 (hr) |
| PT (1) | PT2576618T (hr) |
| RS (1) | RS56368B1 (hr) |
| RU (2) | RU2567805C2 (hr) |
| SG (2) | SG10201504092TA (hr) |
| SI (1) | SI2576618T1 (hr) |
| TN (1) | TN2012000555A1 (hr) |
| TW (2) | TWI602917B (hr) |
| UY (1) | UY33407A (hr) |
| WO (1) | WO2011150008A1 (hr) |
| ZA (1) | ZA201208525B (hr) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| MX2013001845A (es) | 2010-08-16 | 2013-08-27 | Amgen Inc | Polipetidos que enlazan miostatina, composiciones y metodos. |
| TWI761912B (zh) | 2010-11-30 | 2022-04-21 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| HUE038570T2 (hu) * | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával |
| JO3820B1 (ar) * | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| CN113831406A (zh) | 2012-08-24 | 2021-12-24 | 中外制药株式会社 | FcγRIIb特异性Fc区变体 |
| NZ628446A (en) | 2012-09-13 | 2017-06-30 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
| US20150266950A1 (en) | 2012-10-24 | 2015-09-24 | Celgene Corporation | Methods for treating anemia |
| CN110041427B (zh) * | 2013-03-15 | 2023-05-23 | 本质生命科学有限公司 | 抗铁调素抗体及其用途 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US10935554B2 (en) | 2013-08-23 | 2021-03-02 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT) |
| NZ730186A (en) | 2014-09-22 | 2020-04-24 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| US10307480B2 (en) | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| CA2966925C (en) | 2014-11-24 | 2023-08-29 | Somalogic, Inc. | Nucleic acid compounds for binding growth differentiation factor 11 |
| PE20171111A1 (es) | 2014-12-19 | 2017-08-07 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso |
| EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
| US20180031579A1 (en) | 2015-02-12 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| CA2982810A1 (en) * | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CN113896789A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| JP2019504064A (ja) | 2016-01-08 | 2019-02-14 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| JP6823167B2 (ja) | 2016-06-13 | 2021-01-27 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | ミオスタチン阻害剤の使用および併用療法 |
| WO2018025982A1 (ja) | 2016-08-05 | 2018-02-08 | 中外製薬株式会社 | Ｉｌ－８関連疾患の治療用又は予防用組成物 |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| CN106770517A (zh) * | 2016-12-16 | 2017-05-31 | 青岛科技大学 | 一种检测力竭运动后小鼠骨骼肌肌肉生长抑制素含量的方法 |
| US11352417B2 (en) | 2016-12-22 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| HUE061656T2 (hu) | 2017-01-06 | 2023-07-28 | Scholar Rock Inc | Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával |
| BR112020000127A2 (pt) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | método para selecionar um hidrolisado de soja, e, glicoproteína |
| CN115925882A (zh) | 2017-12-22 | 2023-04-07 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| EP3731864A1 (en) * | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche SA | Anti-vegf antibodies and methods of use |
| BR112020013336A2 (pt) | 2018-01-31 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário. |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| AU2019227531A1 (en) | 2018-02-28 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| AU2019226551A1 (en) | 2018-03-01 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition |
| US11054389B2 (en) | 2018-03-19 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| SG11202011970TA (en) | 2018-08-27 | 2020-12-30 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| TW202024639A (zh) | 2018-08-30 | 2020-07-01 | 美商再生元醫藥公司 | 用於將蛋白質複合物定特徵之方法 |
| CN113195532A (zh) * | 2018-12-18 | 2021-07-30 | 瑞泽恩制药公司 | 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法 |
| AU2020208396A1 (en) | 2019-01-16 | 2021-05-20 | Regeneron Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
| WO2020231992A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| CA3150234C (en) | 2019-09-24 | 2023-12-12 | Robert Stairs | Systems and methods for chromatography use and regeneration |
| EP4065086A1 (en) | 2019-11-25 | 2022-10-05 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| MX2022008973A (es) | 2020-01-21 | 2022-08-11 | Regeneron Pharma | Metodos de desglicosilacion para electroforesis de proteinas glicosiladas. |
| WO2022047108A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| JP2023551446A (ja) | 2020-11-25 | 2023-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 非水膜乳化を使用した持続放出製剤 |
| EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
| KR20230150300A (ko) | 2021-03-03 | 2023-10-30 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질 점도를 정량화하고 변경시키기 위한 시스템 및 방법 |
| BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ｐｈ建模及控制之系統及方法 |
| US20230129265A1 (en) | 2021-10-26 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| EP1333035A3 (en) | 1993-03-19 | 2004-07-07 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| CA2331410C (en) | 1998-05-06 | 2009-07-14 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
| EE200200025A (et) | 1999-07-20 | 2003-04-15 | Pharmexa A/S | Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| KR20150107899A (ko) * | 2002-12-20 | 2015-09-23 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
| BRPI0410927A (pt) | 2003-06-02 | 2006-06-27 | Wyeth Corp | métodos terapêuticos e profiláticos para distúrbios neuromusculares |
| SG153874A1 (en) | 2003-12-31 | 2009-07-29 | Schering Plough Ltd | Neutralizing epitope-based growth enhancing vaccine |
| JP2007526337A (ja) | 2004-03-02 | 2007-09-13 | アクセルロン ファーマ インコーポレーテッド | Ａｌｋ７およびミオスタチン阻害剤ならびにその使用 |
| ATE557042T1 (de) | 2004-03-23 | 2012-05-15 | Lilly Co Eli | Anti-myostatin-antikörper |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| CN101001642A (zh) | 2004-08-12 | 2007-07-18 | 惠氏公司 | 使用gdf－8抑制剂对糖尿病、肥胖症和心血管病的联合治疗 |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| DOP2006000093A (es) * | 2005-04-25 | 2007-01-31 | Pfizer | Anticuerpos contra miostatina |
| US7888486B2 (en) | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| CA2624976A1 (en) * | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| MX2008007324A (es) | 2005-12-06 | 2009-03-04 | Amgen Inc | Usos de antagonistas de miostatina. |
| US7699146B1 (en) | 2006-04-02 | 2010-04-20 | Fox Factory, Inc. | Suspension damper having inertia valve and user adjustable pressure-relief |
| PT2374818E (pt) | 2006-06-02 | 2013-02-13 | Regeneron Pharma | Anticorpos com elevada afinidade para o receptor il-6 humano |
| JP2009545313A (ja) * | 2006-08-03 | 2009-12-24 | オリコ・リミテッド | ミオスタチンアンタゴニスト |
| JP5058261B2 (ja) * | 2006-09-05 | 2012-10-24 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| CN100586476C (zh) * | 2006-10-13 | 2010-02-03 | 中国人民解放军第四军医大学 | 一种Myostatin特异性抗体的治疗性疫苗及其制备方法 |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AU2008324243B2 (en) | 2007-11-05 | 2012-03-08 | Novartis Ag | 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| TWI784538B (zh) | 2008-08-14 | 2022-11-21 | 美商艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| AR074777A1 (es) * | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| MY153078A (en) | 2009-04-27 | 2014-12-31 | Novartis Ag | Compositions and methods for increasing muscle growth |
| PT2975051T (pt) | 2009-06-26 | 2021-05-04 | Regeneron Pharma | Anticorpos biespecíficos rapidamente isolados com formato de imunoglobulina nativa |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| HUE038570T2 (hu) | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
-
2011
- 2011-05-17 JO JOP/2011/0164A patent/JO3340B1/ar active
- 2011-05-24 AR ARP110101772A patent/AR081221A1/es active IP Right Grant
- 2011-05-25 NZ NZ603529A patent/NZ603529A/en unknown
- 2011-05-25 SI SI201131297T patent/SI2576618T1/sl unknown
- 2011-05-25 PE PE2012002209A patent/PE20130226A1/es active IP Right Grant
- 2011-05-25 ES ES11726005.9T patent/ES2647389T3/es active Active
- 2011-05-25 CA CA2800581A patent/CA2800581C/en active Active
- 2011-05-25 WO PCT/US2011/037837 patent/WO2011150008A1/en active Application Filing
- 2011-05-25 PL PL11726005T patent/PL2576618T3/pl unknown
- 2011-05-25 JP JP2013512186A patent/JP5896993B2/ja active Active
- 2011-05-25 BR BR112012029986-7A patent/BR112012029986B1/pt active IP Right Grant
- 2011-05-25 PT PT117260059T patent/PT2576618T/pt unknown
- 2011-05-25 TW TW100118221A patent/TWI602917B/zh active
- 2011-05-25 MX MX2012013369A patent/MX2012013369A/es active IP Right Grant
- 2011-05-25 HU HUE11726005A patent/HUE037140T2/hu unknown
- 2011-05-25 SG SG10201504092TA patent/SG10201504092TA/en unknown
- 2011-05-25 RU RU2012156938/10A patent/RU2567805C2/ru active
- 2011-05-25 UY UY0001033407A patent/UY33407A/es unknown
- 2011-05-25 CN CN201180025908.2A patent/CN102933602B/zh active Active
- 2011-05-25 MX MX2015005551A patent/MX357145B/es unknown
- 2011-05-25 KR KR1020127033587A patent/KR101859911B1/ko active IP Right Grant
- 2011-05-25 US US13/115,170 patent/US8840894B2/en active Active
- 2011-05-25 EP EP11726005.9A patent/EP2576618B1/en active Active
- 2011-05-25 MY MYPI2012004862A patent/MY157109A/en unknown
- 2011-05-25 RU RU2015143242A patent/RU2710156C2/ru active
- 2011-05-25 LT LTEP11726005.9T patent/LT2576618T/lt unknown
- 2011-05-25 RS RS20170931A patent/RS56368B1/sr unknown
- 2011-05-25 NO NO11726005A patent/NO2576618T3/no unknown
- 2011-05-25 SG SG2012081964A patent/SG185455A1/en unknown
- 2011-05-25 DK DK11726005.9T patent/DK2576618T3/en active
- 2011-05-25 TW TW105109351A patent/TW201701903A/zh unknown
- 2011-05-25 AU AU2011258342A patent/AU2011258342B2/en active Active
-
2012
- 2012-11-12 IL IL223003A patent/IL223003A/en active IP Right Grant
- 2012-11-13 CR CR20120577A patent/CR20120577A/es unknown
- 2012-11-13 ZA ZA2012/08525A patent/ZA201208525B/en unknown
- 2012-11-14 NI NI201200171A patent/NI201200171A/es unknown
- 2012-11-20 DO DO2012000295A patent/DOP2012000295A/es unknown
- 2012-11-23 GT GT201200318A patent/GT201200318A/es unknown
- 2012-11-23 CL CL2012003283A patent/CL2012003283A1/es unknown
- 2012-11-23 TN TNP2012000555A patent/TN2012000555A1/en unknown
- 2012-11-26 EC ECSP12012309 patent/ECSP12012309A/es unknown
- 2012-12-26 CO CO12233131A patent/CO6620013A2/es unknown
-
2014
- 2014-08-18 US US14/462,085 patent/US9260515B2/en active Active
-
2015
- 2015-12-18 US US14/974,147 patent/US9890212B2/en active Active
-
2017
- 2017-10-05 HR HRP20171499TT patent/HRP20171499T1/hr unknown
- 2017-10-11 CY CY20171101065T patent/CY1119445T1/el unknown
-
2018
- 2018-01-02 US US15/860,200 patent/US20190023777A1/en not_active Abandoned
-
2022
- 2022-10-11 US US18/045,588 patent/US20240067712A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171499T1 (hr) | Protutijela za humani gdf8 | |
| US20210332117A1 (en) | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies | |
| ES2401536T3 (es) | Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden | |
| US10934349B2 (en) | Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody | |
| ES2361917T3 (es) | Inhibidores del receptor 1 del factor de crecimiento de fibroblastos y procedimiento de tratamiento de los mismos. | |
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| EP2970457A2 (en) | Dual specific binding proteins directed against tnf | |
| EA034767B1 (ru) | Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения | |
| HRP20140982T1 (hr) | Ljudska anti-il-23 antitijela, pripravci, postupci i upotrebe | |
| JP2020536109A5 (hr) | ||
| RU2012128651A (ru) | Антитела, связывающиеся преимущественно с внеклеточным доменом 4 человеческого csf-1r, и их применение | |
| RU2011128332A (ru) | Антитело против siglec-15 | |
| JP2014524748A5 (hr) | ||
| KR20160116056A (ko) | 항-ｉｌ-12/ｉｌ-23 항체 | |
| JP2016524592A5 (hr) | ||
| CN108064249A (zh) | 抗tnf/抗il-23双特异性抗体 | |
| AU2015313827B2 (en) | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| JP2019510739A5 (hr) | ||
| JP2012523417A5 (hr) | ||
| JP2019530427A5 (hr) | ||
| TW201233395A (en) | Methods for treating psoriasis | |
| AU2022200690B2 (en) | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists | |
| CA2931978A1 (en) | Compositions and methods for treating osteoarthritis | |
| TWI454481B (zh) | 結合ＴＧＦ－α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體 | |
| AR124286A1 (es) | Proteínas de unión a il-7 y su uso en tratamientos médicos |